FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice

Justet, A.; Ghanem, Mada; Boghanim, T.; Hachem, Melissa; Vasarmidi, Eirini; Jaillet, Madeleine; Vadel, A.; Joannes, Audrey; Mordant, Pierre; Bonniaud, Philippe; Kolb, Martin; Ling, Lei; Cazes, Aurélie; Mal, Hervé; Mailleux, A.; Crestani, Bruno

doi:10.1165/rcmb.2021-0246oc

Cited by 12 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported that serum FGF19 was inversely associated with the fibrosis degree of alcoholic hepatitis and NAFLD (5,7). The overexpression of FGF19 in mice was associated with a marked decrease in lung fibrosis and fibrosis markers (32), suggesting that FGF19 may have an anti-fibrotic effect. Another study demonstrated that serum FGF19 was not associated with the presence of cirrhosis in primary biliary cirrhosis (6).…”

Section: Discussionmentioning

confidence: 91%

Serum Fibroblast Growth Factor 19 as a Biomarker in Hepatitis B Virus-Related Liver Disease

Miao

et al. 2022

Hepat Mon

View full text Add to dashboard Cite

Background: Past research has found that fibroblast growth factor 19 (FGF19) is associated with several hepatic disorders, such as alcoholic liver disease and primary biliary cirrhosis. However, there is currently a lack of relevant studies on the relationship between FGF19 and hepatitis B virus (HBV)-related liver disease. Objectives: This study aimed to assess the role of serum FGF19 as a new biomarker for HBV-related liver disease and provide scientific data to show the clinical value of this biomarker. Methods: A retrospective study included 37 patients with chronic hepatitis B (CHB), 33 patients with HBV-related cirrhosis (HBV-cirrhosis), and 32 patients with HBV-related hepatocellular carcinoma (HBV-HCC). Furthermore, 33 normal people were randomly selected as healthy controls. The serum levels of FGF19 were measured by ELISA. Results: Serum FGF19 levels were increased sequentially in the CHB group, HBV-cirrhosis group, and HBV-HCC group. Furthermore, serum FGF19 levels positively correlated with alpha-fetoprotein, prothrombin time, international normalized ratio, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl-transferase, alkaline phosphatase, total bile acid, serum markers for liver fibrosis, ascites, cirrhosis, Child-Pugh classification and model for end-stage liver disease sodium (MELD-Na) score, while negatively correlated with platelet count, prothrombin activity, and albumin. The diagnostic threshold of serum FGF19 for HBV-related HCC was 165.32 pg/mL, with a sensitivity of 81.25% and specificity of 58.57%. Conclusions: Serum FGF19 levels are positively associated with cholestasis, hepatocyte damage, and liver fibrosis but negatively correlated with liver synthetic function and liver functional reserve in HBV-related liver disease. Diverse changes in serum FGF19 may be used as a predictive marker for the progression of HBV-related liver disease. In addition, serum FGF19 has a potential role in monitoring carcinogenesis in patients with HBV-related liver disease.

show abstract

Section: Discussionmentioning

confidence: 91%

Serum Fibroblast Growth Factor 19 as a Biomarker in Hepatitis B Virus-Related Liver Disease

Miao

et al. 2022

Hepat Mon

View full text Add to dashboard Cite

show abstract

“…The predictive markers found in this study do not only relate to neuroinflammation but may be present during systemic inflammation in general. Although these markers are known to be involved in inflammatory and/or immune responses, some of the molecules are implicated in other pathophysiological processes such as fibrosis in inflammatory conditions, i.e., liver, myocardial, and pulmonary fibrosis [ 62 , 63 , 64 , 65 ]. We cannot rule out that some of the markers are elevated as a result of fibrotic tissue formation around the EVD and, therefore, may vary with the number of days with EVD insertion.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Markers as Predictors of Shunt Dependency and Functional Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage

et al. 2023

View full text Add to dashboard Cite

The mechanisms underlying post-hemorrhagic hydrocephalus (PHH) development following subarachnoid hemorrhage (SAH) are not fully understood, which complicates informed clinical decisions regarding the duration of external ventricular drain (EVD) treatment and prevents the prediction of shunt-dependency in the individual patient. The aim of this study was to identify potential inflammatory cerebrospinal fluid (CSF) biomarkers of PHH and, thus, shunt-dependency and functional outcome in patients with SAH. This study was a prospective observational study designed to evaluate inflammatory markers in ventricular CSF. In total, 31 Patients with SAH who required an EVD between June 2019 and September 2021 at the Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark, were included. CSF samples were collected twice from each patient and analyzed for 92 inflammatory markers via proximity extension assay (PEA), and the prognostic ability of the markers was investigated. In total, 12 patients developed PHH, while 19 were weaned from their EVD. Their 6-month functional outcome was determined with the modified Rankin Scale. Of the 92 analyzed inflammatory biomarkers, 79 were identified in the samples. Seven markers (SCF, OPG, LAP TGFβ1, Flt3L, FGF19, CST5, and CSF1) were found to be predictors of shunt dependency, and four markers (TNFα, CXCL5, CCL20, and IL8) were found to be predictors of functional outcome. In this study, we identified promising inflammatory biomarkers that are able to predict (i) the functional outcome in patients with SAH and (ii) the development of PHH and, thus, the shunt dependency of the individual patients. These inflammatory markers may have the potential to be employed as predictive biomarkers of shunt dependency and functional outcome following SAH and could, as such, be applied in the clinic.

show abstract

“…Respectively, knockout and inhibition reduced myofibroblast differentiation and profibrotic signalling. Myofibroblast differentiation may also be inhibited by protective growth factors such as fibroblast growth factor 19 (FGF 19) and bone morphogenic protein 4 (BMP4) 21,22 …”

Section: Pathogenesismentioning

confidence: 99%

“…Myofibroblast differentiation may also be inhibited by protective growth factors such as fibroblast growth factor 19 (FGF 19) and bone morphogenic protein 4 (BMP4). 21,22…”

Section: Fibroblast Activitymentioning

confidence: 99%

Contemporary Concise Review 2022: Interstitial lung disease

Smith

Jenkins

2023

Respirology

View full text Add to dashboard Cite

SUMMARY OF KEY POINTS Novel genetic associations for idiopathic pulmonary fibrosis (IPF) risk have been identified. Common genetic variants associated with IPF are also associated with chronic hypersensitivity pneumonitis. The characterization of underlying mechanisms, such as pathways involved in myofibroblast differentiation, may reveal targets for future treatments. Newly identified circulating biomarkers are associated with disease progression and mortality. Deep learning and machine learning may increase accuracy in the interpretation of CT scans. Novel treatments have shown benefit in phase 2 clinical trials. Hospitalization with COVID‐19 is associated with residual lung abnormalities in a substantial number of patients. Inequalities exist in delivering and accessing interstitial lung disease specialist care.

show abstract

FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice

Cited by 12 publications

References 61 publications

Serum Fibroblast Growth Factor 19 as a Biomarker in Hepatitis B Virus-Related Liver Disease

Serum Fibroblast Growth Factor 19 as a Biomarker in Hepatitis B Virus-Related Liver Disease

Inflammatory Markers as Predictors of Shunt Dependency and Functional Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage

Contemporary Concise Review 2022: Interstitial lung disease

Contact Info

Product

Resources

About